ePub
Citation
Print
| Korean J Lab Med. 2010 Dec;30(6):575-579. Korean. Published online December 02, 2010. https://doi.org/10.3343/kjlm.2010.30.6.575 | |
| Copyright © 2010 The Korean Society for Laboratory Medicine | |
Minki Kim, M.D.,1
Jin Kyung Lee, M.D.,1
Young Jun Hong, M.D.,1
Seok-Il Hong, M.D.,1
Hye Jin Kang, M.D.,2
and Yoon Hwan Chang , M.D. 1
| |
|
1Department of Laboratory Medicine, Korea Cancer Center Hospital, Seoul, Korea. | |
|
2Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea. | |
| Corresponding author: Yoon Hwan Chang, M.D. Department of Laboratory Medicine, Korea Cancer Center Hospital, 215-4 Gongneung-dong, Nowon-gu, Seoul 139-706, Korea. Tel: +82-2-970-2492, Fax: +82-2-973-7143,
| |
| Received May 27, 2010; Revised August 30, 2010; Accepted October 14, 2010. | |
|
Abstract
| |
|
Background
Late-onset neutropenia (LON) following rituximab therapy has been reported in recent years. However, its incidence has not been reported in Korea. The aim of this study is to investigate the incidence of LON after rituximab therapy in Korean patients with diffuse large B-cell lymphoma (DLBCL).
Methods
Ninety-eight cases of DLBCL treated with rituximab between 2004 and 2008 were evaluated. We identified LON as defined by the neutrophil count of <1.5×109/L without apparent cause after the recovery of neutrophil count following rituximab therapy. Bone marrow aspiration and biopsy specimens at the time of neutropenia were available for retrospective review in only 5 of the patients.
Results
LON was observed in 15 (15.3%) of the 98 patients. In the bone marrow specimens of the 5 patients, promyelocytes were relatively increased and the maturation index of the granulopoiesis was 2:1-3:1, which reflects maturation arrest.
Conclusions
The incidence of LON following rituximab therapy was 15.3% in Korean patients with DLBCL. Although there are several hypotheses about the causative mechanisms of LON, we suggest that maturation arrest at the promyelocyte stage of granulopoiesis may be one of the mechanisms involved in the development of LON. |
|
Keywords: Rituximab; Late-onset neutropenia; Maturation arrest |
|
|
Figures
|
|
|
|
Tables
|
|
|
|
Notes
|
This study was supported by a grant from the Radiation Bio-resource Research Program, Korea Institute of Radiological and Medical Sciences (740802).
|
References
|
| 1. | Terrier B, Ittah M, Tourneur L, Louache F, Soumelis V, Lavie F, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007;92:e20–e23. 
|
| 2. | Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008;25:374–379.
|
| 3. | Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007;18:364–369.
|
| 4. | Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003;121:913–918.
|
| 5. | Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:921–923.
|
| 6. | Saikia TK, Menon H, Advani SH. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. Ann Oncol 2001;12:1493–1494.
|
| 7. | Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002;26:597–600.
|
| 8. | Voog E, Morschhauser F, Solal-Céligny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691–2694.
|
| 9. | Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009;84:414–417.
|
| 10. | Hirayama Y, Kohda K, Konuma Y, Hirata Y, Kuroda H, Fujimi Y, et al. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab. Intern Med 2009;48:57–60.
|
| 11. | Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47:1013–1017.
|
| 12. | Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106:795–802.
|
